469 related articles for article (PubMed ID: 30977114)
1. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.
Eijkelenkamp K; Osinga TE; Links TP; van der Horst-Schrivers ANA
Clin Genet; 2020 Jan; 97(1):39-53. PubMed ID: 30977114
[TBL] [Abstract][Full Text] [Related]
2. Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.
Vicha A; Taieb D; Pacak K
Endocr Relat Cancer; 2014 Jun; 21(3):R261-77. PubMed ID: 24500761
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma.
Lussey-Lepoutre C; Bellucci A; Morin A; Buffet A; Amar L; Janin M; Ottolenghi C; Zinzindohoué F; Autret G; Burnichon N; Robidel E; Banting B; Fontaine S; Cuenod CA; Benit P; Rustin P; Halimi P; Fournier L; Gimenez-Roqueplo AP; Favier J; Tavitian B
Clin Cancer Res; 2016 Mar; 22(5):1120-9. PubMed ID: 26490314
[TBL] [Abstract][Full Text] [Related]
4. SDHB knockout and succinate accumulation are insufficient for tumorigenesis but dual SDHB/NF1 loss yields SDHx-like pheochromocytomas.
Armstrong N; Storey CM; Noll SE; Margulis K; Soe MH; Xu H; Yeh B; Fishbein L; Kebebew E; Howitt BE; Zare RN; Sage J; Annes JP
Cell Rep; 2022 Mar; 38(9):110453. PubMed ID: 35235785
[TBL] [Abstract][Full Text] [Related]
5. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
[TBL] [Abstract][Full Text] [Related]
6. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
[TBL] [Abstract][Full Text] [Related]
7. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications.
Imperiale A; Moussallieh FM; Roche P; Battini S; Cicek AE; Sebag F; Brunaud L; Barlier A; Elbayed K; Loundou A; Bachellier P; Goichot B; Stratakis CA; Pacak K; Namer IJ; Taïeb D
Neoplasia; 2015 Jan; 17(1):55-65. PubMed ID: 25622899
[TBL] [Abstract][Full Text] [Related]
8. Serum Succinate/Fumarate Ratio in Patients With Paraganglioma/Pheochromocytoma Attending an Endocrine Oncogenetic Unit.
Bancel LP; Masso V; Dessein AF; Aubert S; Leteurtre E; Coppin L; Odou MF; Cao CD; Cardot-Bauters C; Pigny P
J Clin Endocrinol Metab; 2023 Aug; 108(9):2343-2352. PubMed ID: 36848172
[TBL] [Abstract][Full Text] [Related]
9. SDHx mutation and pituitary adenoma: can in vivo 1H-MR spectroscopy unravel the link?
Branzoli F; Salgues B; Marjańska M; Laloi-Michelin M; Herman P; Le Collen L; Delemer B; Riancho J; Kuhn E; Jublanc C; Burnichon N; Amar L; Favier J; Gimenez-Roqueplo AP; Buffet A; Lussey-Lepoutre C
Endocr Relat Cancer; 2023 Feb; 30(2):. PubMed ID: 36449569
[TBL] [Abstract][Full Text] [Related]
10. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
[TBL] [Abstract][Full Text] [Related]
11. Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis.
Papathomas TG; Gaal J; Corssmit EP; Oudijk L; Korpershoek E; Heimdal K; Bayley JP; Morreau H; van Dooren M; Papaspyrou K; Schreiner T; Hansen T; Andresen PA; Restuccia DF; van Kessel I; van Leenders GJ; Kros JM; Looijenga LH; Hofland LJ; Mann W; van Nederveen FH; Mete O; Asa SL; de Krijger RR; Dinjens WN
Eur J Endocrinol; 2014 Jan; 170(1):1-12. PubMed ID: 24096523
[TBL] [Abstract][Full Text] [Related]
12. MITOCHONDRIA: Succinate dehydrogenase subunit B-associated phaeochromocytoma and paraganglioma.
Dona M; Neijman K; Timmers HJLM
Int J Biochem Cell Biol; 2021 May; 134():105949. PubMed ID: 33609747
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas.
Moog S; Lussey-Lepoutre C; Favier J
Endocr Relat Cancer; 2020 Dec; 27(12):R451-R463. PubMed ID: 33112834
[TBL] [Abstract][Full Text] [Related]
14. The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma.
Wang Y; Liu B; Li F; Zhang Y; Gao X; Wang Y; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1274239. PubMed ID: 37867526
[TBL] [Abstract][Full Text] [Related]
15. Metabolomic Urine Profile: Searching for New Biomarkers of SDHx-Associated Pheochromocytomas and Paragangliomas.
Martins RG; Gonçalves LG; Cunha N; Bugalho MJ
J Clin Endocrinol Metab; 2019 Nov; 104(11):5467-5477. PubMed ID: 31504671
[TBL] [Abstract][Full Text] [Related]
16. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.
Rai SK; Bril F; Hatch HM; Xu Y; Shelton L; Kalavalapalli S; Click A; Lee D; Beecher C; Kirby A; Kong K; Trevino J; Jha A; Jatav S; Kriti K; Luthra S; Garrett TJ; Guingab-Cagmat J; Plant D; Bose P; Cusi K; Hromas RA; Tischler AS; Powers JF; Gupta P; Bibb J; Beuschlein F; Robledo M; Calsina B; Timmers H; Taieb D; Kroiss M; Richter S; Langton K; Eisenhofer G; Bergeron R; Pacak K; Tevosian SG; Ghayee HK
Metabolism; 2020 Sep; 110():154297. PubMed ID: 32562798
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation.
Kamai T; Murakami S; Arai K; Nishihara D; Uematsu T; Ishida K; Kijima T
BMC Cancer; 2022 Mar; 22(1):289. PubMed ID: 35300626
[TBL] [Abstract][Full Text] [Related]
18. Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.
Lamy C; Tissot H; Faron M; Baudin E; Lamartina L; Pradon C; Al Ghuzlan A; Leboulleux S; Perfettini JL; Paci A; Hadoux J; Broutin S
J Clin Endocrinol Metab; 2022 Sep; 107(10):2801-2810. PubMed ID: 35948272
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance and peculiarities of succinate dehydrogenase B and hypoxia inducible factor 1α expression in parasympathetic versus sympathetic paragangliomas.
Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Valdés N; Astudillo A; Balbín M; Pitiot AS; Jiménez-Fonseca P; Scola B; Tena I; Molina-Garrido MJ; Sevilla MA; Beristein E; Forga L; Villabona C; Oriola J; Halperin I; Suarez C; Chiara MD
Head Neck; 2019 Jan; 41(1):79-91. PubMed ID: 30549360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
